Skip to main content

Table 1 Characteristics of 49 patients with ovarian mucinous carcinoma according to invasive patterns

From: Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature

  Ovarian mucinous carcinoma
with infiltrative invasion
Ovarian mucinous carcinoma
with expansile invasion
p-Value
Variables n = 25 n = 24
Age (years)    0.16
 < 51 16 (64) 10 (42)  
 ≥ 51 9 (36) 14 (58)  
FIGO stage (%)    0.26
 I 16 (64) 20 (84)  
 II 1 (4) 1 (4)  
 III 6 (24) 1 (4)  
 IV 2 (8) 2 (8)  
Tumor site (%)    0.35
 Unilateral 21 (84) 23 (96)  
 Bilateral 4 (4) 1 (4)  
Standard surgery (%)    0.78
 Yes 15 (60) 13 (54)  
 No 10 (40) 11 (46)  
Peritoneal cytology (%)    0.78
 Positive 12 (48) 10 (42)  
 Negative 13 (52) 14 (58)  
Residual tumor diameter at PDS (%)    0.58
 No residual tumor 18 (72) 20 (83)  
 < 1.0 cm 1 (4) 1 (4)  
 ≥ 1.0 cm 6 (24) 3 (13)  
Adjuvant chemotherapy (%)    0.02
 Not done 4 (16) 12 (50)  
 Done 21 (84) 12 (50)  
Regimen of the adjuvant chemotherapy    
 Paclitaxel and carboplatin 5 (24) 2 (17) 0.20
 Platinum-based therapy a 16 (76) 10 (83)  
Response rate of adjuvant chemotherapy for patients with residual tumor which received adjuvant chemotherapy (%)    0.20
 CR/PR 3 (43) 3 (100)  
S D/PD 4 (57) 0 (0)  
Recurrence (%)    < 0.01
 Yes 13 (52) 2 (8)  
 No 12 (48) 22 (92)  
  1. Abbreviations:SD standard deviation; FIGO International Federation of Gynecology and Obstetrics; PDS primary debulking surgery; cm centimeter; CR complete response; PR partial response; SD stable disease; PD progressive disease
  2. a Platinum-based therapy included the combination with cyclophosphamide, doxorubicin, and cisplatin, the combination with cyclophosphamide and cisplatin, the combination with etoposide and cisplatin, and the combination with irinotecan and nedaplatin
\